Risk-Reducing Mastectomy: — How to Decide

NCCN reports that BRCA1 carriers face a lifetime breast cancer risk of approximately 65–72%. For comparison, the lifetime risk in the general population is approximately 13%. BRCA2 carriers face a somewhat lower but still substantially elevated risk, reported in the range of approximately 45–69%. These are averages across carriers; your personal risk may be shaped by other factors, including your family history pattern and other variants present. Your genetic counsellor can give you a figure that accounts for your specific history.

Surveillance is a clinically accepted alternative, not a lesser one. Annual MRI and mammography, combined with regular clinical breast exams, are designed to detect breast cancer early — at a stage when outcomes are generally much better. The honest limitation is that surveillance does not lower your risk; it monitors it. Whether it is right for you depends on how well you can tolerate ongoing uncertainty and whether you are committed to attending every scheduled scan. Oncologists who work in high-risk prevention do not push patients towards surgery as the obviously correct answer.

No. NCCN reports a risk reduction of approximately 90% in BRCA carriers, not 100%. Some breast tissue — including tissue near the skin, the nipple area if preserved, and the chest wall — remains after surgery, and with it a small residual risk. This is worth knowing before the operation, not as a reason to avoid it, but because people who expect zero risk afterwards are sometimes distressed to learn that ongoing surveillance is still recommended. The residual risk is small, but it does not disappear entirely.

There is no single correct age, and NCCN guidance does not set a mandatory age for the surgery. The conversation typically begins from the mid-twenties for BRCA1 carriers, and a little later for BRCA2 carriers, reflecting the different ages at which risk begins to accumulate meaningfully. Family plans, psychological readiness, and personal preference all affect timing. What NCCN recommends at all ages is that high-risk individuals are in a structured surveillance programme while any surgical decision is being considered.

Start surveillance and tell your oncologist you are not ready. Entering a structured MRI and mammography programme means you are being actively monitored while you take the time you need. Indecision is not the same as inaction when you are in a surveillance programme. Ask for a referral to a genetic counsellor if you have not already seen one — they are trained to help people work through exactly this kind of decision without steering them towards a particular outcome. Some people reach clarity quickly; others take years. Both are normal.

Ask how many risk-reducing mastectomies they have performed in women without a cancer diagnosis. Ask what type of mastectomy they recommend for you and why. Ask whether nipple-sparing is possible in your case. Ask whether reconstruction can be done at the same time, and if so, whether you should see a plastic surgeon first. Ask what recovery involves and how long before normal activity resumes. Ask what surveillance will look like after surgery. A surgeon who works regularly with high-risk patients should be able to answer all of these directly.